Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$7.53
$0.18(2.91%)
At close: 4:00 PM EDT
$7.53
$0.18(2.91%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous Close$6.37
Volume133.76K
Average Volume (3M)190.06K
Market Cap
$221.84M
Enterprise Value$194.55
Total Cash (Recent Filing)$25.64M
Total Debt (Recent Filing)$25.54M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding22,224,396
10 Day Avg. Volume102,023
30 Day Avg. Volume190,056
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.50Price Target Upside79.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)$82.61M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Product EconomicsStrong year-over-year revenue growth alongside a 67% gross margin indicates expanding demand and attractive product-level economics. If sustained, this combination can provide the operating leverage and reinvestment capacity needed to support broader commercialization over the next several quarters.
Amrozi Prescription And Prescriber MomentumAmrozi is showing meaningful commercial traction through both higher prescription volume and a broader prescriber base. More than 4,500 dermatology prescribers and sequential prescription growth suggest improving adoption, creating a stronger foundation for recurring product revenue.
Improving Profitability TrajectoryPositive EBITDA and a sharply reduced GAAP loss demonstrate meaningful progress toward breakeven as revenue scales. Management’s expectation for positive EBITDA through the remainder of 2026, combined with stable gross margin, supports the potential for improving earnings quality.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow show that reported commercial progress has not yet translated into self-funding operations. Continued cash burn could constrain investment flexibility and increase reliance on the existing cash balance or external financing.
Profitability Remains UnprovenLosses have narrowed substantially, but the company still lacks consistent GAAP profitability and produces negative returns on equity. Until revenue growth converts into durable net income, earnings remain vulnerable to execution setbacks and cost increases.
Payer Friction Limits AdoptionLimited high-quality formulary coverage can slow prescribing, increase administrative hurdles, and weaken reimbursement conversion for Amrozi. Further growth and ASP improvement therefore depend on continued payer wins and health-plan execution rather than demand alone.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $221.84M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Nov 11, 2026 which is in 63 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on Aug 12, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.012.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is 0.02.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 22,224,396 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 3.421%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (79.28% Upside)
$13.50 (79.28% Upside)
Blogger Sentiment
Neutral
DERM Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Journey Medical Corp
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum—notably strong top-line growth (total revenue +23% YoY), robust Amrozi prescription growth (≈20% sequential), expanding prescriber footprint (>40% increase since 2025 year-end), positive EBITDA and materially narrowed GAAP losses—while also acknowledging remaining headwinds around payer friction (only ~38% high-quality formulary coverage), some product-level softness (QBREXZA in the quarter), and timing uncertainty for international out-licensing. Management highlighted continued investments (new reps, marketing, a new product launch) to capitalize on momentum. On balance, the positive operational and financial progress substantially outweighs the noted challenges.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(79.28% Upside)
Technical Analysis
Ownership Overview
19.48% Insiders
14.17% Mutual Funds
32.15% Other Institutional Investors
30.92% Public Companies and
Individual Investors